Mankind Pharma is no longer just making pills-it’s making waves.
In FY2024-25, the pharmaceutical major ramped up its advertising and sales promotion spend to a whopping ₹755 crore, up 25% from the previous year. This big brand push comes as the company’s annual revenue surged 19% to ₹12,207 crore, fueled by growth across its prescription and consumer healthcare segments.
From condoms to pregnancy kits, Mankind’s consumer-first strategy is leaning hard into advertising to turn OTC products into cultural staples.
Leading the charge are its viral and emotionally resonant campaigns:
• Manforce Condoms played up humor and pop culture-hijacking everything from April Fool’s Day to election season with cheeky, meme-worthy content that trended across platforms.
• Prega News stayed true to its heart-touching storytelling, backed by grassroots efforts like WhatsApp support groups and rural awareness drives.
• Gas-O-Fast and HealthOk reached millions through large-scale sampling drives at events like the Kumbh Mela, bringing visibility where it matters.
This aggressive brand-building play isn’t random. With India’s consumer healthcare market projected to grow at 9–10% CAGR through FY2029, Mankind is positioning itself for long-term dominance-urban and rural, online and offline.
Despite the spending spree, the company managed strong margins. Adjusted EBITDA rose 25% to ₹3,159 crore, with profit after tax at ₹2,007 crore. Even with increased borrowing, the company remains confident in its forward-looking investments.
Now ranked as India’s fourth-largest pharma company by value, Mankind is doubling down on growth areas like fertility, biologics, and critical care.
In a market where most pharma players whisper, Mankind Pharma is shouting with style-and substance.
